Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer

R. Vatapalli, V. Sagar, Y. Rodriguez, J. C. Zhao, K. Unno, S. Pamarthy, B. Lysy, J. Anker, H. Han, Y. A. Yoo, M. Truica, Z. R. Chalmers, F. Giles, J. Yu, D. Chakravarti, B. Carneiro and S. A. Abdulkadir ()
Additional contact information
R. Vatapalli: Northwestern University Feinberg School of Medicine
V. Sagar: Northwestern University Feinberg School of Medicine
Y. Rodriguez: Northwestern University Feinberg School of Medicine
J. C. Zhao: Northwestern University Feinberg School of Medicine
K. Unno: Northwestern University Feinberg School of Medicine
S. Pamarthy: Pennsylvania Biotechnology Center
B. Lysy: Northwestern University Feinberg School of Medicine
J. Anker: Northwestern University Feinberg School of Medicine
H. Han: Northwestern University Feinberg School of Medicine
Y. A. Yoo: Northwestern University Feinberg School of Medicine
M. Truica: Northwestern University Feinberg School of Medicine
Z. R. Chalmers: Northwestern University Feinberg School of Medicine
F. Giles: Developmental Therapeutics Consortium
J. Yu: Northwestern University Feinberg School of Medicine
D. Chakravarti: Northwestern University Feinberg School of Medicine
B. Carneiro: Brown University
S. A. Abdulkadir: Northwestern University Feinberg School of Medicine

Nature Communications, 2020, vol. 11, issue 1, 1-15

Abstract: Abstract The histone methyltransferase DOT1L methylates lysine 79 (K79) on histone H3 and is involved in Mixed Lineage Leukemia (MLL) fusion leukemogenesis; however, its role in prostate cancer (PCa) is undefined. Here we show that DOT1L is overexpressed in PCa and is associated with poor outcome. Genetic and chemical inhibition of DOT1L selectively impaired the viability of androgen receptor (AR)-positive PCa cells and organoids, including castration-resistant and enzalutamide-resistant cells. The sensitivity of AR-positive cells is due to a distal K79 methylation-marked enhancer in the MYC gene bound by AR and DOT1L not present in AR-negative cells. DOT1L inhibition leads to reduced MYC expression and upregulation of MYC-regulated E3 ubiquitin ligases HECTD4 and MYCBP2, which promote AR and MYC degradation. This leads to further repression of MYC in a negative feed forward manner. Thus DOT1L selectively regulates the tumorigenicity of AR-positive prostate cancer cells and is a promising therapeutic target for PCa.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-18013-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18013-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-18013-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().